JPS6119605B2 - - Google Patents

Info

Publication number
JPS6119605B2
JPS6119605B2 JP50015230A JP1523075A JPS6119605B2 JP S6119605 B2 JPS6119605 B2 JP S6119605B2 JP 50015230 A JP50015230 A JP 50015230A JP 1523075 A JP1523075 A JP 1523075A JP S6119605 B2 JPS6119605 B2 JP S6119605B2
Authority
JP
Japan
Prior art keywords
salt
solution
sodium
cephem
ylthiomethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP50015230A
Other languages
English (en)
Japanese (ja)
Other versions
JPS50126817A (OSRAM
Inventor
Emu Guriin Jeemusu
Emu Inderikaato Josefu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23765656&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS6119605(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of JPS50126817A publication Critical patent/JPS50126817A/ja
Publication of JPS6119605B2 publication Critical patent/JPS6119605B2/ja
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP50015230A 1974-02-22 1975-02-05 Expired JPS6119605B2 (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US444622A US3928592A (en) 1974-02-22 1974-02-22 Antibiotic pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JPS50126817A JPS50126817A (OSRAM) 1975-10-06
JPS6119605B2 true JPS6119605B2 (OSRAM) 1986-05-17

Family

ID=23765656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50015230A Expired JPS6119605B2 (OSRAM) 1974-02-22 1975-02-05

Country Status (24)

Country Link
US (1) US3928592A (OSRAM)
JP (1) JPS6119605B2 (OSRAM)
AR (1) AR203895A1 (OSRAM)
AT (1) AT356264B (OSRAM)
BE (1) BE825653A (OSRAM)
CA (1) CA1043261A (OSRAM)
CH (1) CH620929A5 (OSRAM)
CS (1) CS189689B2 (OSRAM)
DD (1) DD117807A5 (OSRAM)
DE (1) DE2506622C2 (OSRAM)
DK (1) DK153919C (OSRAM)
ES (1) ES434976A1 (OSRAM)
FR (1) FR2261772B1 (OSRAM)
GB (1) GB1493676A (OSRAM)
HU (1) HU174129B (OSRAM)
IE (1) IE40671B1 (OSRAM)
IL (1) IL46650A (OSRAM)
NL (1) NL179976C (OSRAM)
PH (1) PH12058A (OSRAM)
PL (1) PL109311B1 (OSRAM)
SE (1) SE406153B (OSRAM)
SU (1) SU659094A3 (OSRAM)
YU (1) YU41875A (OSRAM)
ZA (1) ZA75975B (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054738A (en) * 1975-12-22 1977-10-18 Eli Lilly And Company Sodium cefamandole crystalline forms
JPS5283956A (en) * 1976-01-01 1977-07-13 Lilly Co Eli Antibiotic method and medical composition
JPS5329936A (en) * 1976-08-31 1978-03-20 Takeda Chem Ind Ltd Antibiotic composition
JPS5711909A (en) * 1980-06-23 1982-01-21 Shionogi & Co Ltd Stable freeze-dried preparation of beta-lactam
CA2011365A1 (en) * 1989-03-06 1990-09-06 Eugene L. Inman Diluent formulation for daptomycin
JP4873207B2 (ja) * 2001-02-26 2012-02-08 東レ・ファインケミカル株式会社 光学活性カルボン酸クロリドの精製方法
CN100554271C (zh) * 2007-07-27 2009-10-28 苏州中联化学制药有限公司 抗菌素头孢孟多酯钠的合成方法
CN101880290B (zh) * 2010-06-28 2012-03-07 海南新中正制药有限公司 头孢孟多酯钠的制备方法
WO2013057197A1 (en) * 2011-10-20 2013-04-25 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the formylation of cefamandole
WO2013057196A1 (en) * 2011-10-20 2013-04-25 Dsm Sinochem Pharmaceuticals Netherlands B.V. Process for the preparation of cefamandole nafate
US9834567B1 (en) * 2014-12-16 2017-12-05 Tianjin University Crystalline form of cefamandole nafate compound, preparation and preparing method thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1767891C3 (de) * 1968-06-28 1980-10-30 Pfizer Verfahren zur Herstellung von wäßrigen arzneilichen Lösungen für die parenterale, perorale und lokale Anwendung mit einem Gehalt an einem Tetracyclinderivat
US3641021A (en) * 1969-04-18 1972-02-08 Lilly Co Eli 3 7-(ring-substituted) cephalosporin compounds

Also Published As

Publication number Publication date
DK65575A (OSRAM) 1975-10-20
DE2506622C2 (de) 1987-02-26
SE7501985L (OSRAM) 1975-08-25
PH12058A (en) 1978-10-18
AU7833975A (en) 1976-08-19
ATA128475A (de) 1979-09-15
DD117807A5 (OSRAM) 1976-02-05
FR2261772A1 (OSRAM) 1975-09-19
PL109311B1 (en) 1980-05-31
CH620929A5 (OSRAM) 1980-12-31
JPS50126817A (OSRAM) 1975-10-06
AR203895A1 (es) 1975-10-31
SE406153B (sv) 1979-01-29
IL46650A (en) 1977-10-31
HU174129B (hu) 1979-11-28
ZA75975B (en) 1976-09-29
SU659094A3 (ru) 1979-04-25
BE825653A (fr) 1975-08-18
CS189689B2 (en) 1979-04-30
IE40671L (en) 1975-08-22
GB1493676A (en) 1977-11-30
DK153919B (da) 1988-09-26
AT356264B (de) 1980-04-25
FR2261772B1 (OSRAM) 1980-01-04
IE40671B1 (en) 1979-07-18
YU41875A (en) 1982-05-31
IL46650A0 (en) 1975-05-22
ES434976A1 (es) 1976-12-16
NL179976B (nl) 1986-07-16
CA1043261A (en) 1978-11-28
NL7502045A (nl) 1975-08-26
DK153919C (da) 1989-02-06
DE2506622A1 (de) 1975-08-28
NL179976C (nl) 1986-12-16
US3928592A (en) 1975-12-23

Similar Documents

Publication Publication Date Title
AU663471B2 (en) Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
KR0180798B1 (ko) 결정성 페니실린 유도체, 그의 제법 및 용도
JPH08507519A (ja) 結晶性セフチオフル遊離酸
JPS6119605B2 (OSRAM)
US8853389B2 (en) Process for refining cefmetazole sodium
US4470980A (en) Method of increasing oral absorption of β-lactam antibiotics
JPS6145626B2 (OSRAM)
JPH10511967A (ja) エンロフロキサシンの注射用もしくは注入用溶液
EP0329286B1 (en) Zinc ceftiofur complexes
JPS5925377A (ja) メトロニダゾ−ルとｎ，ｎ−ジメチルグリシンとのエステルおよびその酸付加湿
JP2703964B2 (ja) セファロスポリン抗生物質類
AU2010295269B2 (en) Compositions and methods for treating bacterial infections using ceftaroline
US11124526B2 (en) Crystalline beta-lactamase inhibitor
KR930007263B1 (ko) 세프-3-엠-4-카르복실산 유도체의 제조방법
KR800000604B1 (ko) 비경구용 0-포밀세파만돌 나트륨염제제의 제조방법
CN116284051B (zh) 一种头孢地尼烷酸衍生物及其制备方法和应用
JP2761005B2 (ja) セファロスポリン含有注射用組成物
JPS6254313B2 (OSRAM)
KR101142582B1 (ko) β-락타마제 효소에 저항성을 갖는 세팔로스포린 에스테르화합물 및 이의 염
JPS63154622A (ja) セフアロスポリン誘導体を有効成分とする哺乳動物用抗菌剤
JP3012986B2 (ja) セフェム化合物及びその製造法
JPH0692970A (ja) トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
SU1140688A3 (ru) Способ получени низших алканоилоксиалкиловых сложных диэфиров производного цефалоспорина
US4001409A (en) Injectable formulations of 7-[D-α-amino-α-(p-hydroxyphenyl)acetamido]-3-(1,2,3-triazol-5-ylthiomethyl)-3-cephem-4-carboxylic acid
JPH0315632B2 (OSRAM)